Shanghai Yizhong Pharmaceutical Co., Ltd.

SSE:688091.SS

44.59 (CNY) • At close June 9, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

2025 Q12024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q1
Revenue 71.0324.73947.45152.96468.37980.68778.771108.03192.469.63494.45337.52934.3424.0780000000
Cost of Revenue 13.2224.0352.5962.9693.7334.7985.0356.7737.1035.1786.2583.2162.3180.2960000000
Gross Profit 57.810.70444.85549.99564.64675.88973.737101.25885.29664.45688.19434.31332.0243.7820000000
Gross Profit Ratio 0.8140.1490.9450.9440.9450.9410.9360.9370.9230.9260.9340.9140.9330.9270000000
Reseach & Development Expenses 9.27711.8610.0149.7345.5965.7437.7226.3822.6033.1772.211.0821.4560.3043.8575.2363.8435.4174.2353.5694.673
General & Administrative Expenses 6.214-15.21616.8875.8668.3755.22813.4696.2598.548-2.835.334-0.9452.223-6.61910.5862.8613.149-4.557.2750.7370.747
Selling & Marketing Expenses 28.209-17.26845.36727.90525.58227.85730.24733.74414.78629.55648.0626.644.7731.8240.4940-00000
SG&A 34.423-36.89262.29238.69933.39940.82143.71640.00323.33426.72653.3965.6956.996-4.79511.082.8613.149-4.557.2750.7370.747
Other Expenses -2.38746.645-27.076-2.634-0.976-0.037-2.667-1.2750.14-3.547-3.3822.982-0.2143.783-4.807-6.722-5.5047.676-0.0011.441-0.005
Operating Expenses 41.31318.00245.2348.43338.99546.60148.59849.62526.07726.35652.2249.7598.238-0.70910.131-6.722-5.5048.5436.265.7467.087
Operating Income 16.498-10.674-6.9991.56225.65129.28832.88758.00866.14646.92143.91830.91729.83211.442-8.498-6.722-5.504-7.165-4.743-4.364-5.569
Operating Income Ratio 0.232-2.252-0.1470.0290.3750.3630.4170.5370.7160.6740.4650.8240.8692.8060000000
Total Other Income Expenses Net -1.008-7.2756.161-2.634-0.9766.3375.081-1.275-1.824-0.608-0.695-0.7230-0.60.6000-0.0010-0.005
Income Before Tax 15.49-33.282-0.8375.46733.46935.62430.21956.73464.32346.31343.22330.19429.83210.842-7.898-6.722-5.504-7.165-4.744-4.364-5.574
Income Before Tax Ratio 0.218-7.023-0.0180.1030.4890.4420.3840.5250.6960.6650.4580.8050.8692.6590000000
Income Tax Expense 1.304-5.588-0.9980.1374.2914.6943.7057.6499.2987.6240.036-0.041-0.913-4.8571.6337.945-0.0541.3781.517-0.5350.081
Net Income 14.186-27.6950.1615.33129.17830.9326.51449.08555.02538.68943.18730.23530.74416.127-7.898-6.722-5.504-7.165-4.744-4.364-5.574
Net Income Ratio 0.2-5.8440.0030.1010.4270.3830.3370.4540.5960.5560.4570.8060.8953.9550000000
EPS 0.07-0.1770.0010.0260.180.20.170.310.350.240.410.290.210.19-0.099-0.084-0.047-0.09-0.06-0.055-0.052
EPS Diluted 0.07-0.1770.0010.0260.180.20.170.310.350.240.410.290.210.19-0.099-0.084-0.047-0.09-0.06-0.055-0.052
EBITDA 14.212-27.801-0.7318.63636.57838.00532.64158.55166.15447.93245.33431.78831.42611.015-7.584-11.996-5.504-9.391-5.443-4.233-5.507
EBITDA Ratio 0.2-5.866-0.0150.1630.5350.4710.4140.5420.7160.6880.480.8470.9152.7010000000